Post Reply
3801-3820 of 10899
Come on' look at what he wrote on Genting HK US$
Listen to him...sure pok....(it's so obivous...gamers won & CASH OUT now)
Let's the truth to show the strength of this share on 24th Sep (when Micro Port HK starts trading)
http://www.businessweek.com/news/2010-09-09/microport-scientific-seeks-198-million-from-h-k-ipo.html
INSIDERS' SECRET NEWS :- Heard from the Elite Traders' Circle that the BIG BOSS of SHENG SIONG , supermarket chain owner Mr. Lim , BOUGHT MASSIVE LOT on this Counter GENTING HK $USD , yesterday MON morning when the price peak during lunch , he is HOLDING Long term for capital appreciation .
insidertips ( Date: 21-Sep-2010 19:09) Posted:
INSIDER NEWS UPDATE ! Yes i heard from Insider circle , RICH TYCOON from HONGKONG had purchased alot this afternoon , this counter will SHOOT to the moon latest this weekend ! BUY IN FAST NOW to GRAB before all SOLD OUT !!! FAST !
bankit ( Date: 21-Sep-2010 18:10) Posted:
| if not selling = keen to push it to 1.10.. yes, i'm in.. :P |
|
|
|
Wow, you got so much insider news!
How many lots have you bought today? Today, volume only ~15,500 lots, not much leh!
insidertips ( Date: 21-Sep-2010 19:09) Posted:
INSIDER NEWS UPDATE ! Yes i heard from Insider circle , RICH TYCOON from HONGKONG had purchased alot this afternoon , this counter will SHOOT to the moon latest this weekend ! BUY IN FAST NOW to GRAB before all SOLD OUT !!! FAST !
bankit ( Date: 21-Sep-2010 18:10) Posted:
| if not selling = keen to push it to 1.10.. yes, i'm in.. :P |
|
|
|
yeah... counting down to it's peer listing soon... hope this gem will rocket further... cheers! Happy trading to all:)
risktaker ( Date: 21-Sep-2010 09:49) Posted:
I hear Micro IPO fixed @ HK 6.10 = SGD $1.07 - 120 times over subscribe.
My TP: Biosensors may reached $1.26
Biosensor = A BUY anything below a $1.00 is dirt cheap :P
BOSAYOR HUAT AH
|
|
didnt see it relate to a rise...
insidertips ( Date: 21-Sep-2010 19:09) Posted:
INSIDER NEWS UPDATE ! Yes i heard from Insider circle , RICH TYCOON from HONGKONG had purchased alot this afternoon , this counter will SHOOT to the moon latest this weekend ! BUY IN FAST NOW to GRAB before all SOLD OUT !!! FAST !
bankit ( Date: 21-Sep-2010 18:10) Posted:
| if not selling = keen to push it to 1.10.. yes, i'm in.. :P |
|
|
|
INSIDER NEWS UPDATE ! Yes i heard from Insider circle , RICH TYCOON from HONGKONG had purchased alot this afternoon , this counter will SHOOT to the moon latest this weekend ! BUY IN FAST NOW to GRAB before all SOLD OUT !!! FAST !
bankit ( Date: 21-Sep-2010 18:10) Posted:
| if not selling = keen to push it to 1.10.. yes, i'm in.. :P |
|
if not selling = keen to push it to 1.10.. yes, i'm in.. :P
Anyone here Keen to push this baby up to 1.10 & Above?
Overbought some correction to be expected...
What the reason for the drop today...
I hear Micro IPO fixed @ HK 6.10 = SGD $1.07 - 120 times over subscribe.
My TP: Biosensors may reached $1.26
Biosensor = A BUY anything below a $1.00 is dirt cheap :P
BOSAYOR HUAT AH
A few years ago Biosensor ever hit $1.45...looks lioke it is possible with the listing of MicroPort H.K successful IPO price at upper range H.K$6.10 
| Camper wrote: |
| Camper wrote: |
DBS• Initiate coverage on Biosensors with Buy recommendation
and target price of S$ 1.20.
DBS Research is initiating coverage on Biosensors with Buy
recommendation and target price of S$ 1.20, which offers
43% potential upside. Our analyst projects earnings CAGR of
24% over the next two, driven by market share gains led by
leading product, BioMatrix, the first biodegradable polymer
DES. Catalysts ahead include securing approvals for sale of
BioMatrix in Japan and China, with collective market size of
US$800m – US$1bn. Biosensors is also a prime target for
take-over. The upcoming MicroPort’s HK IPO serves as rerating
catalyst. |
Anyone know Microport's IPO price?
|
Related News:Stocks · Asia .MicroPort Said to Raise $198 Million in Hong Kong Initial Public Offering
By Fox Hu - Sep 20, 2010 5:53 PM GMT+0800
Email Share
Business ExchangeTwitterDeliciousDiggFacebookLinkedInNewsvinePropellerYahoo! BuzzPrint MicroPort Scientific Corp., which makes equipment for keyhole surgery, raised about HK$1.54 billion ($198.3 million) selling shares at the top of its price range in an initial public offering in Hong Kong, according to two people with knowledge of the transaction.
The Shanghai-based producer of coronary stents sold 252.7 million shares at HK$6.10 apiece, said the people, who declined to be identified because the information was private. Terms for the sale earlier showed that MicroPort had planned to sell shares at HK$4.60 to HK$6.10.
Credit Suisse Group AG and Piper Jaffray Asia Securities managed the sale, according to the company’s IPO prospectus. MicroPort plans to start trading on Sept. 24 under ticker number 853, the prospectus said. Adam Harper, a Hong Kong-based Credit Suisse spokesman, declined to comment. Alex Ko, chief executive officer of Piper Jaffray Asia Holdings Ltd., was not available to comment.
Proceeds of the IPO will be used to develop new products, acquire businesses and expand the company’s production facilities, the prospectus said. The company has an option to sell an additional 37.9 million shares after the listing, the prospectus said.
MicroPort makes so-called interventional and minimally invasive devices to treat vascular diseases. The company supplies more than 1,100 hospitals across China, according to its website.
Chairman Chang Zhaohua, who founded the company in 1998, said on Sept. 12 that MicroPort had overcome doubts about medical devices made in China to acquire a 28.9 percent share of the country’s market for heart stents.
When it reaches 1.20 some analysts will up it to $1.70. Congratulations to the loyal longterm investors.
starlene ( Date: 20-Sep-2010 11:00) Posted:
| Ya shd be tmrl....DBS Vickers also9 rate buy besides Nomura |
|
Ya shd be tmrl....DBS Vickers also9 rate buy besides Nomura
should be this week......21st-25thSept (TCT2010).
starlene ( Date: 20-Sep-2010 10:31) Posted:
Next tue 28Sept definitely head higher...
|
Price target: SGD 1.2
Peer listing to drive rerating? (II)
Microport IPO price likely to be at the high-end. Based on our channel checks, we understand that market response to Microport's IPO is good. At the high end of the indicated range (HK$4.60~HK$6.10), Microport's IPO valuation is at 25x FY10 P/E (Dec-end), according to the company. In contrast, Biosensors is trading at 18x FY11F P/E (Mar-end) on a strong FY12F EPS growth of 52% (12x FY12F P/E), driven by the impending approval of Nobori in Japan.
Similar product, but different geographical exposure. Both Microport and Biosensors are broadly single-product companies focused on drug-eluting stents. However, Microport is a pure China play while Biosensors has a more diversified growth profile with three pillars of growth: i) core franchise which is well-established in the EU, ii) China exposure via 50%-owned JV JWMS, iii) Japan exposure via licensing agreement with Terumo.
Recent CE approval reflects group's strategy to expand portfolio. BIG recently received CE approval for longer length versions of its flagship BioMatrix Flex, which offers a significant opportunity to increase market penetration as an estimated 15% of DES usage involve long lengths. We believe this reflects the group's strategy to expand its product offerings, exemplified by the recent acquisition of CardioMind.
Reiterate BUY - catalysts yet to play out. BIG has rerated on the news of Microport's IPO (+7% this morning). We believe the stock will continue to trend towards our PT of S$1.20, driven by catalysts such as BioFreedom's clinical trial results (to be announced next Tuesday at TCT conference) and the Japanese approval of Nobori by Terumo.
Valuation Methodology and Investment Risks:
Note: Ratings and Price Targets are as of the date of the most recently published report (http://www.nomura.com/research) rather than the date of this email. We value Biosensors on a SOTP methodology- DCF for is base business, Terumo royalties and BioMatrix (9.7% WACC), 9.2x exit P/E to account for DES business valuation. We value its 50% stake in JWMS at 22x P/E. Key risks: i) High exposure to weak EUR; ii) Stent pricing pressure in China.
Nomura Global Equity Research
Institutional Investor 2010 Ranking
#1 China Research, #1 Japan Research, #2 Asia Research, #2 Europe Res
Price (16 Sep 2010): SGD 0.84
Research analyst: Jit Soon Lim
65.6433.6969
jitsoon.lim@nomura.com
Research analyst: Yuan Yiu Tsai
65-6433-6964
yuanyiu.tsai@nomura.com
ublish Date: 17 Sep 2010
P
|
|
|
Beside the good news and upgrade ratings, there is a glimmer of high hope of being sought after. You heard anything? I know JNJ is anxiously looking at big pharma with proven potentials for takeover. Will they have one of their sights on BIG?
Next tue 28Sept definitely head higher...
|
Price target: SGD 1.2
Peer listing to drive rerating? (II)
Microport IPO price likely to be at the high-end. Based on our channel checks, we understand that market response to Microport's IPO is good. At the high end of the indicated range (HK$4.60~HK$6.10), Microport's IPO valuation is at 25x FY10 P/E (Dec-end), according to the company. In contrast, Biosensors is trading at 18x FY11F P/E (Mar-end) on a strong FY12F EPS growth of 52% (12x FY12F P/E), driven by the impending approval of Nobori in Japan.
Similar product, but different geographical exposure. Both Microport and Biosensors are broadly single-product companies focused on drug-eluting stents. However, Microport is a pure China play while Biosensors has a more diversified growth profile with three pillars of growth: i) core franchise which is well-established in the EU, ii) China exposure via 50%-owned JV JWMS, iii) Japan exposure via licensing agreement with Terumo.
Recent CE approval reflects group's strategy to expand portfolio. BIG recently received CE approval for longer length versions of its flagship BioMatrix Flex, which offers a significant opportunity to increase market penetration as an estimated 15% of DES usage involve long lengths. We believe this reflects the group's strategy to expand its product offerings, exemplified by the recent acquisition of CardioMind.
Reiterate BUY - catalysts yet to play out. BIG has rerated on the news of Microport's IPO (+7% this morning). We believe the stock will continue to trend towards our PT of S$1.20, driven by catalysts such as BioFreedom's clinical trial results (to be announced next Tuesday at TCT conference) and the Japanese approval of Nobori by Terumo.
Valuation Methodology and Investment Risks:
Note: Ratings and Price Targets are as of the date of the most recently published report (http://www.nomura.com/research) rather than the date of this email. We value Biosensors on a SOTP methodology- DCF for is base business, Terumo royalties and BioMatrix (9.7% WACC), 9.2x exit P/E to account for DES business valuation. We value its 50% stake in JWMS at 22x P/E. Key risks: i) High exposure to weak EUR; ii) Stent pricing pressure in China.
Nomura Global Equity Research
Institutional Investor 2010 Ranking
#1 China Research, #1 Japan Research, #2 Asia Research, #2 Europe Res
Price (16 Sep 2010): SGD 0.84
Research analyst: Jit Soon Lim
65.6433.6969
jitsoon.lim@nomura.com
Research analyst: Yuan Yiu Tsai
65-6433-6964
yuanyiu.tsai@nomura.com
ublish Date: 17 Sep 2010
P
|
$1.20 can be reached this week? I have a feeling too.
SGD $1.00 Already !!!
DJ Shandong Weigao Target Raised To HK$40 Vs HK$30 By Deutsche
News China Medical 4X oversubscribed
Microport????
Thinking of entering this counter...think should be able to reach 1.20
